Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berinert for Refractory Antibody Mediated Rejection
NCT03221842Phase 3Terminated
- Sponsor
- CSL Limited
- Start
- Nov 2017
- Primary completion
- Jan 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in antibody mediated rejection (AMR) comparing C1-INH with Placebo (2 arms). Primary endpoint: Percent of Participants With Loss-of-response During Treatment Period 2 (TP2) at 38 weeks. Started Nov 2017; status: terminated.
02
Drugs
c1-esterase inhibitor
03
Conditions
antibody mediated rejection (AMR)
Beyond the preview
Go deeper on NCT03221842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03221842.